NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action (Type 1.5 inhibitor) which results in inhibition of both the catalytic and scaffolding functions of the SRC kinase, thereby providing a complete shutdown of the signaling pathway.
NXP900 completed a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers, supporting the phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents
